Naringenin pretreatment attenuates hepatic ischemia-reperfusion injury by activating the PI3K-Akt signaling pathway

Figure 5 In vitro naringenin ameliorates hypoxia/reoxygenation-induced injury in AML12 cells. A: In vitro AML12 cells experimental procedure; B: Cell counting kit-8 experiment detects cell viability (n = 6); C: Reactive oxygen species in situ detection assay; D: Quantification of mean reactive oxygen species fluorescence intensity (n = 3); E: Apoptosis detection by flow cytometry; F: Statistical analysis of apoptotic cell rate (n = 3); G: Western blots showing protein expression levels of p-phosphatidylinositol 3-kinase, p-protein kinase B, Bax and Bcl-2; H-K: Densitometric quantification of p-phosphatidylinositol 3-kinase, p-protein kinase B, Bax and Bcl-2 (n = 3). Scale bar: 50 μm. ^aP < 0.05 vs the hypoxia/reoxygenation group, ^bP < 0.05 vs the control group. NAR: Naringenin; IRI: Ischemia-reperfusion injury; PI3K: Phosphatidylinositol 3-kinase; Akt: Protein kinase B; H/R: Hypoxia/reoxygenation.